Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders

Clinical Pharmacology and Therapeutics
P van BrummelenM A Schalekamp

Abstract

Blood pressure, cardiac output, plasma volume, renin, and aldosterone were measured in 13 patients with essential hypertension on placebo and after 1, 4, and 12 wk on hydrochlorothiazide 100 mg daily. In 9 patients the same variables were also measured after 24 and 36 wk. Hydrochlorothiazide lowered mean arterial pressure (p less than 0.01). Cardiac output was reduced after 4 and 12 wk of treatment, followed by a return to placebo levels. Stroke volume changed in the same way but heart rate and total peripheral resistance did not differ from placebo values. Plasma volume was reduced after 1 and 24 wk. Renin was permanently elevated (p less than 0.01), but aldosterone rose only during the first 12 wk of treatment. A comparison between responders (greater than 10% fall in mean arterial pressure) and nonresponders (less than 10% fall) revealed different hemodynamic patterns. In responders the initial fall in cardiac output was followed by a return to pretreatment levels, whereas in nonresponders it was permanently reduced. Consequently, total peripheral resistance was lowered only in responders. Nonresponders tended to show a greater degree of plasma volume depletion and greater stimulation of renin and aldosterone, which probably...Continue Reading

Citations

Jan 1, 1987·British Journal of Clinical Pharmacology·E AmbrosioniF V Costa
Jul 5, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Takahiro Iwamoto
Jul 13, 2011·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Yuhei ShigaKeijiro Saku
Apr 18, 2013·American Journal of Hypertension·Gary L SchwartzStephen T Turner
Apr 16, 2013·The Annals of Pharmacotherapy·Danielle Pierini, Katherine Vogel Anderson
Jan 22, 2014·Expert Opinion on Pharmacotherapy·Juan TamargoLuis M Ruilope
Sep 25, 2017·The Journal of Clinical Hypertension·Mai MehannaRhonda M Cooper-DeHoff
Sep 24, 2019·Frontiers in Pharmacology·Robert M Rapoport, Manoocher Soleimani
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·H A Struyker-BoudierH van Essen
Aug 1, 1991·Cardiovascular Drugs and Therapy·P LijnenA Amery
Feb 10, 2006·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Takahiro Iwamoto
Sep 10, 2003·Drugs·Caroline FentonLesley J Scott
Jul 7, 2011·Expert Opinion on Pharmacotherapy·Jujhar Bains, William B Smith
Nov 23, 2012·Expert Opinion on Pharmacotherapy·Amedeo Mugellini, Valentina Nieswandt
Feb 27, 2015·American Journal of Therapeutics·Pramod Reddy, Lori Dupree
Mar 10, 2015·Current Hypertension Reports·Arjun D Sinha, Rajiv Agarwal
Jan 1, 1983·Current Medical Research and Opinion·D B Campbell
Jan 1, 1984·Acta Pharmacologica Et Toxicologica·P Hjemdahl
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·N M Kaplan
Jan 1, 1984·Acta Pharmacologica Et Toxicologica·M Danielson
Apr 2, 2005·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Alun D Hughes
Jun 10, 2010·Expert Review of Cardiovascular Therapy·Julio D Duarte, Rhonda M Cooper-DeHoff
Nov 26, 2010·Expert Review of Cardiovascular Therapy·Alexander Turchin, Paul R Conlin
Sep 3, 2016·Therapeutic Advances in Cardiovascular Disease·Patricio AraosMaría Paz Ocaranza
Feb 1, 1995·British Journal of Pharmacology·P Pickkers, A D Hughes
Mar 18, 2016·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Douglas L Blowey
Jul 27, 2001·Fundamental & Clinical Pharmacology·L GalánJ L Alvarez
May 14, 2005·Expert Review of Cardiovascular Therapy·Marc Maillard, Michel Burnier
Feb 9, 2012·Postgraduate Medicine·David S KountzMayer Ezer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.